Q4 2024 saw 11% sales growth, margin expansion, and strong cash flow, with both Labtech and Medtech segments performing well. Debt reduction and improved working capital position AddLife for a confident 2025 outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.